Autophagy Induced by Micheliolide Alleviates Acute Irradiation-Induced Intestinal Injury Inhibition of the NLRP3 Inflammasome
Overview
Authors
Affiliations
Radiation-induced enteropathy (RIE) is one of the most common and fatal complications of abdominal radiotherapy, with no effective interventions available. Pyroptosis, a form of proinflammatory regulated cell death, was recently found to play a vital role in radiation-induced inflammation and may represent a novel therapeutic target for RIE. To investigate this, we found that micheliolide (MCL) exerted anti-radiation effects . Therefore, we investigated both the therapeutic effects of MCL in RIE and the possible mechanisms by which it may be therapeutic. We developed a mouse model of RIE by exposing C57BL/6J mice to abdominal irradiation. MCL treatment significantly ameliorated radiation-induced intestinal tissue damage, inflammatory cell infiltration, and proinflammatory cytokine release. In agreement with these observations, the beneficial effects of MCL treatment in RIE were abolished in mice. Furthermore, super-resolution microscopy revealed a close association between NLR pyrin domain three and lysosome-associated membrane protein/light chain 3-positive vesicles following MCL treatment, suggesting that MCL facilitates phagocytosis of the NLR pyrin domain three inflammasome. In summary, MCL-mediated induction of autophagy can ameliorate RIE by NLR pyrin domain three inflammasome degradation and identify MCL as a novel therapy for RIE.
Li J, Li X, Liu H Front Pharmacol. 2025; 16:1551115.
PMID: 40051564 PMC: 11882563. DOI: 10.3389/fphar.2025.1551115.
Pharmacological potential of micheliolide: A focus on anti-inflammatory and anticancer activities.
Uddin J, Fatima M, Riaz A, Kamal G, Bin Muhsinah A, Ahmed A Heliyon. 2024; 10(6):e27299.
PMID: 38496875 PMC: 10944196. DOI: 10.1016/j.heliyon.2024.e27299.
Ning J, Chen L, Zeng Y, Xiao G, Tian W, Wu Q Int J Biol Sci. 2024; 20(5):1871-1883.
PMID: 38481804 PMC: 10929204. DOI: 10.7150/ijbs.91112.
Pyroptotic cell death: an emerging therapeutic opportunity for radiotherapy.
Li H, Yang T, Zhang J, Xue K, Ma X, Yu B Cell Death Discov. 2024; 10(1):32.
PMID: 38228635 PMC: 10791972. DOI: 10.1038/s41420-024-01802-0.
Peng Z, Lv X, Wang X, Shang T, Chang J, Salahdiin K Front Pharmacol. 2023; 14:1265177.
PMID: 38094883 PMC: 10716238. DOI: 10.3389/fphar.2023.1265177.